Tevogen Bio Holdings Inc. (TVGNW)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | Co-Founder, CEO & Chairperson | 501k | -- | 1965 |
| Mr. Kirti Desai CPA | Chief Financial Officer | 300k | -- | 1957 |
| Dr. Neal Flomenberg M.D. | Chief Scientific Officer and Global R&D Lead | 350k | -- | 1954 |
| Mr. Stephen Chen M.B.A. | Chief Technical Officer | -- | -- | -- |
| Mr. Mittul Mehta | Chief Information Officer & Head of Tevogen.ai | -- | -- | -- |
| Mr. Tapan V. Shah | Head of Investor Relations & Corporate Development | -- | -- | -- |
| Mr. Sadiq Khan M.B.A. | Chief Commercial Officer & Interim Head of Tevogen Generics | -- | -- | 1962 |
| Mr. David E. Banko CPA | Global Head of Government Affairs & Patient Access | -- | -- | -- |
Tevogen Bio Holdings Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 18
Description
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients. It is also developing TVGN 920 for treating cervical cancer; TVGN 960 for treating oropharyngeal cancer; TVGN 601 for treating MS; and TVGN 930 for treating EBV-associated lymphomas. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available